Pulmonary Fibrosis
170
26
39
79
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
21 trials with published results (12%)
Research Maturity
79 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.8%
15 terminated out of 170 trials
84.0%
-2.5% vs benchmark
9%
15 trials in Phase 3/4
27%
21 of 79 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 79 completed trials
Clinical Trials (170)
DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.
Analysis of Specimens From Individuals With Pulmonary Fibrosis
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Role of Genetic Factors in the Development of Lung Disease
Advanced Imaging for Pulmonary Fibrosis
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment
Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Telomeres Length in Israeli Fibrotic ILD Patients
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Post Acute Sequelae of COVID-19
Explanted Lung Tissues With Pulmonary Fibrosis
The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib